Featured Research

from universities, journals, and other organizations

Safety of biologic treatment for arthritis depends on the drug

Date:
February 15, 2011
Source:
Wiley-Blackwell
Summary:
Some biologic drugs may be safer than others according to a new systematic review. Biologics are a broad class of drugs based on biological molecules. The drugs are used to reduce inflammation in diseases such as rheumatoid arthritis and inflammatory bowel disease.

Some biologic drugs may be safer than others according to a new systematic review by Cochrane researchers. Biologics are a broad class of drugs based on biological molecules. The drugs are used to reduce inflammation in diseases such as rheumatoid arthritis and inflammatory bowel disease.

Related Articles


Although the effectiveness of biologics is now well established, it is thought that some may have rare but serious side effects related to their immune-suppressing activities. Links have been made to increased risk of infections, reactivation of tuberculosis (TB), cancer and congestive heart failure.

The review is based on data from 163 studies focused on nine different biologics used to treat arthritis and other conditions. A total of 50,010 patients took part in the studies. Adverse events and TB reactivation were more likely among those taking biologics compared to controls. Serious side effects, lymphoma and congestive heart failure were no more likely. When compared to each other, two drugs, adalimumab and infliximab, caused more adverse events, whereas abatacept and anakinra were associated with fewer serious adverse events. Taking certolizumab pegol was more likely to result in a serious infection compared to several other biologics.

The researchers say the results should be treated cautiously. "The data provides some guidance for clinicians and patients as regards the safety of different biologic drugs, but we should remember that these are not head-to-head trials." said lead researcher Jasvinder Singh of the Birmingham VA Medical Center in Birmingham, Alabama. "There is still an urgent need for more research into the safety of these drugs, and in particular their comparative safety."

Some adverse events were so rare that it was difficult to establish whether or not they were linked to the drugs. "Biologics did not seem to increase the likelihood of congestive heart failure or cancer compared to placebos, but there were few cases in total, so we can't be very confident about these results," said Singh. "The studies we looked at did show a few more people suffering from tuberculosis with biologics, but again total numbers were low."


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "Safety of biologic treatment for arthritis depends on the drug." ScienceDaily. ScienceDaily, 15 February 2011. <www.sciencedaily.com/releases/2011/02/110215191629.htm>.
Wiley-Blackwell. (2011, February 15). Safety of biologic treatment for arthritis depends on the drug. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2011/02/110215191629.htm
Wiley-Blackwell. "Safety of biologic treatment for arthritis depends on the drug." ScienceDaily. www.sciencedaily.com/releases/2011/02/110215191629.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Din้ Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins